Stock listing
NASDAQ:FBLG FibroBiologics, Inc. Stock
Home listing (NASDAQ) of FibroBiologics, Inc.
Follow FibroBiologics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:FBLG
$0.705 USD -0.135 (-16.1%)
Close on Nov 20, 2026
- Day range
- $0.705 – $0.872 USDNov 20, 2026
- Volume
- 49,626 sharesNov 20, 2026
- Market cap
- $6.34M USDAt the close on Nov 20, 2026 · price × 8.99M shares outstanding
- 52-week range
- $0.620 – $9.598 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $249,592 USDMedian day 116,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FBLG · Home | $0.705 USD | -0.135 (-16.1%) | 49,626 | $0.872 | $0.872 | $0.705 | $0.840 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FBLG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.705 | -0.135 | -16.1% | $0.872 | $0.872 | $0.705 | 49,626 | |
| $0.840 | -0.061 | -6.7% | $0.940 | $0.940 | $0.800 | 86,304 | |
| $0.901 | -0.003 | -0.3% | $0.930 | $0.960 | $0.893 | 78,311 | |
| $0.903 | -0.024 | -2.6% | $0.946 | $0.950 | $0.890 | 97,460 | |
| $0.927 | -0.041 | -4.2% | $1.020 | $1.020 | $0.921 | 35,455 | |
| $0.968 | -0.028 | -2.8% | $1.010 | $1.010 | $0.933 | 34,182 | |
| $0.996 | +0.072 | +7.8% | $0.940 | $1.040 | $0.920 | 54,336 | |
| $0.924 | -0.034 | -3.5% | $0.930 | $0.966 | $0.924 | 59,674 | |
| $0.958 | -0.022 | -2.2% | $0.912 | $0.966 | $0.912 | 59,415 | |
| $0.980 | +0.023 | +2.4% | $0.940 | $0.980 | $0.911 | 41,010 | |
| $0.957 | -0.012 | -1.2% | $1.000 | $1.000 | $0.910 | 81,390 | |
| $0.969 | -0.021 | -2.2% | $1.040 | $1.040 | $0.941 | 59,736 | |
| $0.990 | +0.070 | +7.6% | $0.935 | $0.990 | $0.901 | 41,764 | |
| $0.920 | -0.010 | -1.1% | $0.920 | $0.960 | $0.920 | 42,364 | |
| $0.930 | +0.002 | +0.2% | $0.920 | $0.970 | $0.900 | 20,671 | |
| $0.928 | -0.039 | -4.0% | $0.940 | $0.990 | $0.923 | 17,857 | |
| $0.967 | +0.035 | +3.8% | $0.929 | $0.993 | $0.910 | 32,010 | |
| $0.932 | -0.008 | -0.9% | $0.970 | $0.990 | $0.929 | 26,590 | |
| $0.940 | -0.010 | -1.1% | $0.930 | $0.950 | $0.890 | 156,618 | |
| $0.950 | -0.070 | -6.9% | $1.020 | $1.020 | $0.950 | 111,922 | |
| $1.020 | +0.027 | +2.7% | $0.970 | $1.240 | $0.970 | 399,071 | |
| $0.993 | +0.073 | +7.9% | $0.900 | $1.000 | $0.900 | 127,507 | |
| $0.920 | -0.024 | -2.6% | $0.930 | $0.971 | $0.881 | 94,090 | |
| $0.944 | -0.027 | -2.8% | $0.980 | $0.980 | $0.940 | 170,331 | |
| $0.971 | -0.029 | -2.9% | $1.020 | $1.040 | $0.950 | 36,000 | |
| $1.000 | +0.050 | +5.3% | $0.960 | $1.050 | $0.960 | 156,200 | |
| $0.950 | -0.010 | -1.0% | $1.000 | $1.020 | $0.925 | 109,100 | |
| $0.960 | -0.040 | -4.0% | $1.000 | $1.025 | $0.933 | 80,600 | |
| $1.000 | -0.130 | -11.5% | $1.120 | $1.135 | $0.989 | 152,000 | |
| $1.130 | +0.020 | +1.8% | $1.110 | $1.200 | $1.100 | 182,300 | |
| $1.110 | -0.030 | -2.6% | $1.120 | $1.140 | $1.050 | 71,900 | |
| $1.140 | +0.010 | +0.9% | $1.160 | $1.200 | $1.070 | 233,800 | |
| $1.130 | -0.050 | -4.2% | $1.200 | $1.230 | $1.120 | 210,300 | |
| $1.180 | -0.060 | -4.8% | $1.240 | $1.240 | $1.180 | 94,100 | |
| $1.240 | +0.035 | +2.9% | $1.200 | $1.240 | $1.100 | 148,600 | |
| $1.205 | -0.095 | -7.3% | $1.320 | $1.320 | $1.160 | 140,100 | |
| $1.300 | -0.010 | -0.8% | $1.350 | $1.400 | $1.280 | 107,300 | |
| $1.310 | -0.050 | -3.7% | $1.380 | $1.410 | $1.260 | 191,800 | |
| $1.360 | -0.030 | -2.2% | $1.440 | $1.480 | $1.340 | 241,600 | |
| $1.390 | +0.030 | +2.2% | $1.350 | $1.390 | $1.330 | 55,400 | |
| $1.360 | +0.030 | +2.3% | $1.350 | $1.470 | $1.330 | 258,600 | |
| $1.330 | -0.010 | -0.7% | $1.320 | $1.450 | $1.310 | 87,300 | |
| $1.340 | -0.020 | -1.5% | $1.350 | $1.410 | $1.330 | 95,800 | |
| $1.360 | -0.070 | -4.9% | $1.460 | $1.460 | $1.290 | 116,700 | |
| $1.430 | -0.055 | -3.7% | $1.540 | $1.540 | $1.400 | 130,700 | |
| $1.485 | +0.055 | +3.8% | $1.530 | $1.587 | $1.460 | 105,100 | |
| $1.430 | -0.010 | -0.7% | $1.440 | $1.490 | $1.386 | 117,100 | |
| $1.440 | -0.110 | -7.1% | $1.550 | $1.575 | $1.440 | 177,100 | |
| $1.550 | -0.060 | -3.7% | $1.600 | $1.690 | $1.521 | 174,500 | |
| $1.610 | -0.120 | -6.9% | $1.700 | $1.736 | $1.610 | 107,300 | |
| $1.730 | -0.030 | -1.7% | $1.730 | $1.796 | $1.671 | 83,700 | |
| $1.760 | +0.050 | +2.9% | $1.730 | $1.800 | $1.620 | 135,900 | |
| $1.710 | -0.100 | -5.5% | $1.800 | $1.816 | $1.619 | 166,400 | |
| $1.810 | +0.050 | +2.8% | $1.730 | $1.900 | $1.710 | 210,456 | |
| $1.760 | -0.190 | -9.7% | $1.800 | $1.901 | $1.700 | 366,002 | |
| $1.950 | -0.160 | -7.6% | $2.170 | $2.175 | $1.865 | 639,026 | |
| $2.110 | +0.390 | +22.7% | $1.730 | $2.200 | $1.720 | 1,545,221 | |
| $1.720 | +0.280 | +19.4% | $1.460 | $1.790 | $1.401 | 508,098 | |
| $1.440 | -0.050 | -3.4% | $1.500 | $1.540 | $1.410 | 143,785 | |
| $1.490 | +0.080 | +5.7% | $1.440 | $1.520 | $1.420 | 217,830 | |
| $1.410 | +0.010 | +0.7% | $1.390 | $1.470 | $1.330 | 164,686 | |
| $1.400 | +0.050 | +3.7% | $1.340 | $1.490 | $1.330 | 191,303 | |
| $1.350 | -0.090 | -6.2% | $1.420 | $1.500 | $1.310 | 252,938 | |
| $1.440 | +0.150 | +11.6% | $1.350 | $1.489 | $1.340 | 570,614 | |
| $1.290 | +0.100 | +8.4% | $1.220 | $1.370 | $1.200 | 415,522 |
Splits
1 split · NASDAQ:FBLG · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:FBLG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 19 slides
Latest news
FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
Nov 16, 2026
Closed $0.901 (-0.3%) on Nov 17, 2026
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
Nov 12, 2026
Closed $0.968 (-2.8%) on Nov 12, 2026
FibroBiologics Announces Update On Its Intellectual Property Portfolio
Nov 12, 2026
Closed $0.968 (-2.8%) on Nov 12, 2026
FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents
Nov 5, 2026
Closed $0.957 (-1.2%) on Nov 5, 2026
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
Oct 19, 2026
Closed $0.944 (-2.8%) on Oct 19, 2026
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Oct 14, 2026
Closed $0.95 (-1.0%) on Oct 14, 2026
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
Oct 7, 2026
Closed $1.14 (+0.9%) on Oct 7, 2026
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Sep 29, 2026
Closed $1.31 (-3.7%) on Sep 29, 2026
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
Sep 17, 2026
Closed $1.49 (+3.8%) on Sep 17, 2026
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Sep 3, 2026
Closed $1.76 (-9.7%) on Sep 3, 2026
FibroBiologics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 59 in the last 12 months · 121 in all · newest Nov 16, 2026 · oldest 2024
- Decks
- 2 decks · latest September 2026
Where FibroBiologics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FBLG · Home listing · This page | NASDAQ | United States | USD |
| BOATS:FBLG | BOATS | United States | USD |
| Frankfurt:SG00 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A426UV | Lang & Schwarz | Germany | EUR |
| LS Exchange:A426UV | LS Exchange | Germany | EUR |
Valuation
Price/book 3.5× against a median of 1.0×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.17M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| FibroBiologics, Inc. · NASDAQ:FBLG | US$6.34M | US$5.17M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.34 |
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| ZEO ScientifiX Inc. · OTC:ZEOX | US$6.51M | US$5.27M | n/a | 1.0× | n/a | n/a | −106.2% | n/a | 0.54 |
| GT Biopharma, Inc. · NASDAQ:GTBP | US$6.33M | −US$3.60M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.57 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Median of the others | US$6.20M | US$1.08M | 1.0× | 1.0× | −216.1% | 0.0× | 1.44 |
Forecasts
1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.00 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Pete O’Heeron | Chairman/Founder/CEO |
| Jason D. Davis | Chief Financial Officer |
| Ruben Garcia | General Counsel |
| Hamid Khoja | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Pete O’Heeron | Chairman/Founder/CEO |
| Brain Health | Director |
| Kathleen Rubins | Board of Directors |
| Leigh Steinberg | Board of Directors |
| Richard C. Cilento | Board of Directors |
| Robert E. Hoffman | Board of Directors |
| Victoria Niklas | Board of Directors |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −0.3% |
| Q2 2026 | Jul 31, 2026 · After close | +12.9% |
| Q1 2026 | May 1, 2026 | +4.5% |
| Q4 2025 | Feb 24, 2026 · After close | −1.6% |
| Q3 2025 | Oct 31, 2025 · After close | +0.3% |
| Q2 2025 | Aug 14, 2025 · After close | −2.5% |
| Q1 2025 | May 14, 2025 · After close | +22.7% |
| Q4 2024 | Mar 31, 2025 · After close | −4.4% |
| Q3 2024 | Nov 12, 2024 · After close | −2.8% |
| Q2 2024 | Aug 7, 2024 · After close | −39.4% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 | +2.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 19 slides | September 2026 |
| Investor Day (December 2023) | Investor day | 33 slides | December 2023 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock and accompanying warrants Closed: US$500,000 raised · US$1.675 a share · Warrants at US$1.55 for 60 months Buyers: Hamid Khoja, Ph.D. (298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares) Insiders: The entire placement was purchased by Chief Scientific Officer Hamid Khoja, Ph.D. Use of proceeds: General corporate purposes and working capital | Sep 17, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) with series A and short-term series B warrants Closed: US$3M raised · US$0.735 a share · Warrants at US$0.735 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Jun 29, 2026 |
| Registered direct offering of registered direct offering Closed: US$2.5M raised | Apr 30, 2026 |
| Registered direct offering of common stock, with concurrent private placement of unregistered warrants Closed: US$1.7M raised · US$0.33 a share · Warrants at US$0.33 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Dec 16, 2025 |
| Registered direct offering of common stock, with concurrent private placement of unregistered warrants Closed: US$1.5M raised · US$0.335 a share · Warrants at US$0.335 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Nov 25, 2025 |
| Registered direct offering of common stock and pre-funded warrants, with concurrent private placement of unregistered warrants Closed: US$4M raised · US$0.3303 a share · Warrants at US$0.3303 for 60 months Buyers: existing shareholder (3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares, paid with gold coins) Use of proceeds: General corporate purposes, including the satisfaction of debt | Nov 20, 2025 |
| Convertible promissory notes (advances under SEPA) Tranche closed: US$5M in the latest tranche · D. Boral Capital LLC Dealers: D. Boral Capital LLC (lead) Buyers: YA II PN LTD. (Yorkville) (Up to $25 million of common stock over two years; first $15 million advanced via convertible promissory notes, $5 million funded); YA II PN, LTD. (Yorkville) (third $5 million tranche of convertible promissory notes under the SEPA) Use of proceeds: General corporate purposes, including R&D programs and the upcoming Phase 1/2 diabetic foot ulcer clinical trial | Jun 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||||
| Cost of revenue | 832.0K | 573.0K | 437.0K | 94.0K | ||||||
| Gross profit | -832.0K | -573.0K | -437.0K | -94.0K | ||||||
| Research and development | 7.41M | 7.41M | 4.50M | 4.50M | 2.37M | 2.37M | 1.15M | 1.15M | 521.0K | 669.0K |
| Selling, general and administrative | 9.24M | 9.23M | 6.52M | 3.32M | 1.06M | 500.0K | ||||
| Operating income | -16.6M | -16.6M | -13.7M | -13.7M | -8.89M | -8.89M | -4.47M | -4.47M | -1.58M | -1.17M |
| Depreciation and amortization | 832.0K | 244.0K | 573.0K | 157.0K | 437.0K | 47.0K | 94.0K | 0 | 1.17M | |
| EBITDA | -15.8M | -16.4M | -13.2M | -13.6M | -8.45M | -8.84M | -4.37M | -1.58M | 0 | |
| Interest expense | 204.0K | 204.0K | 20.0K | 20.0K | 147.0K | 147.0K | 654.0K | 654.0K | 4.00K | |
| Income before tax | -18.6M | -11.2M | -16.5M | -5.12M | -1.58M | -1.17M | ||||
| Income tax | 0 | 0 | 0 | 0 | ||||||
| Net income | -18.6M | -18.6M | -11.2M | -11.2M | -16.5M | -16.5M | -5.12M | -5.12M | -1.58M | -1.17M |
| Earnings per share, basic | -8.35 | -0.42 | -6.79 | -0.34 | -10.15 | -0.68 | -3.15 | -0.18 | -0.97 | -0.72 |
| Earnings per share, diluted | -0.42 | -0.34 | -0.68 | -0.18 |
Balance sheet
| Line | FY2026 | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.89M | 4.89M | 14.0M | 14.0M | 9.16M | 9.16M | 2.27M | 2.27M | 407.0K | |
| Receivables | 300.0K | 300.0K | ||||||||
| Current assets | 6.35M | 6.35M | 14.2M | 14.2M | 9.21M | 9.21M | 2.63M | 2.63M | 468.0K | |
| Property, plant and equipment | 842.0K | 824.0K | 797.0K | |||||||
| Total assets | 9.62M | 9.62M | 16.4M | 16.4M | 11.8M | 11.8M | 4.82M | 4.82M | 468.0K | |
| Accounts payable | 945.0K | 2.70M | 1.44M | 758.0K | 233.0K | |||||
| Current liabilities | 1.76M | 1.76M | 12.7M | 12.7M | 9.18M | 9.18M | 7.07M | 7.07M | 1.76M | |
| Total debt | 2.41M | 10.6M | 1.75M | 7.52M | 1.30M | |||||
| Total liabilities | 3.46M | 3.46M | 13.7M | 13.7M | 10.6M | 10.6M | 8.82M | 8.82M | 1.76M | |
| Shareholders' equity | 6.16M | 6.16M | 2.73M | 2.73M | 1.25M | 1.25M | -4.00M | -4.00M | -1.29M | |
| Shares outstanding | 2.23M | 8.99M | 1.64M | 8.99M | 1.62M | 67.6M | 1.62M | 37.7M | 1.62M | 1.62M |
Cash flow
| Line | FY2026 | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16.4M | -16.4M | -11.9M | -11.9M | -6.40M | -6.40M | -4.07M | -4.07M | -1.41M | -1.17M |
| Capital spending | -262.0K | -262.0K | -184.0K | -184.0K | -495.0K | -495.0K | 0 | 0 | 0 | |
| Free cash flow | -16.7M | -16.7M | -12.1M | -12.1M | -6.90M | -6.90M | -4.07M | -1.41M | -1.17M | |
| Cash from investing | -262.0K | -262.0K | -184.0K | -184.0K | -495.0K | -495.0K | ||||
| Cash from financing | 7.57M | 7.57M | 16.9M | 16.9M | 13.8M | 13.8M | 5.92M | 5.92M | 1.82M | 1.17M |
| Change in cash | -9.09M | -9.09M | 4.82M | 4.82M | 6.90M | 6.90M | 1.86M | 1.86M | 407.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Oct 20, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 20, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Oct 13, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 13, 2026 | Offer document | SEC |
| D | Oct 13, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 8, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 18, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 17, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| D | Sep 15, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 15, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 9, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Sep 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 24, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 31, 2026 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Jul 31, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 17, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Jul 17, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jul 16, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Jul 16, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jul 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2026 | Management or board change | SEC |
| D | Jun 29, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Management or board change | SEC |
| 8-K · Current report | May 6, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 5, 2026 | Offer document | SEC |
| 8-K · Current report | May 5, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | May 5, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 5, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 5, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | May 1, 2026 | Offer document | SEC |
| 8-K · Current report | May 1, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 8-K · Current report | Apr 17, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Apr 9, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 9, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 3, 2026 | Current report | SEC |
| 8-K · Current report | Apr 2, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | Mar 27, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Mar 20, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 31, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 29, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Dec 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 29, 2025 | Meeting notice | SEC |
| S-1 · Registration statement | Dec 23, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Dec 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 18, 2025 | Meeting notice | SEC |
| D | Dec 16, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 15, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 15, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| D | Dec 3, 2025 | Other filings | SEC |
| D | Dec 3, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 25, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 19, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 31, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Jul 18, 2025 | Financing | SEC |
| 8-K · Current report | Jul 18, 2025 | Financing | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 3, 2025 | Current report | SEC |
| 8-K · Current report | Jun 16, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 7, 2025 | Financing | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 3, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 24, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jan 22, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jan 17, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 15, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 10, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 10, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 31, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| S-1 · Registration statement | Dec 30, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 20, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 24, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 28, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2024 | Financing | SEC |
| EFFECT · Notice that a registration is effective | Aug 15, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Aug 13, 2024 | Offer document | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 12, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Jul 8, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 8, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 8, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 27, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 424B4 · Prospectus | Jun 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 18, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jun 18, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 17, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jun 10, 2024 | Offer document | SEC |
| RW · Request to withdraw a registration | Jun 6, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 4, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 15, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 15, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 26, 2024 | Current report | SEC |
| S-1 · Registration statement | Apr 25, 2024 | Offer document | SEC |
| DRS · Draft registration statement | Apr 12, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 29, 2024 | Other filings | SEC |
| 424B4 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 26, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 25, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 15, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Feb 26, 2024 | Other filings | SEC |
This page holds 200 of 244 filings. Open Filings
Cap table
Built by 6ix from FibroBiologics, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 8,989,475
- Fully diluted
- 8,989,475
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 8,989,475 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.55 · expire about Sep 2031 |
| Warrants · US$0.74 · expire about Jun 2031 |
| Warrants · US$0.33 · expire about Dec 2030 |
| Warrants · US$0.34 · expire about Nov 2030 |
| Warrants · US$0.33 · expire about Nov 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 8,989,475 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert E. Hoffman Other companies: CytoDyn Inc. (Chief Financial Officer · Since at least May 15, 2025); Esperion Therapeutics, Inc. (Director · Since at least Apr 1, 2025); TuHURA Biosciences, Inc. (Director · Since at least Apr 11, 2018); Aravive Inc (Director · Oct 12, 2018 – Sep 12, 2019 · Past); Heron Therapeutics, Inc. (CFO & SVP, Finance · Apr 24, 2017 – Dec 19, 2019 · Past); Kura Oncology, Inc. (Director · May 12, 2016 – Jun 22, 2021 · Past); CombiMatrix Corp (Director · May 10, 2016 – Nov 14, 2017 · Past); MabVax Therapeutics Holdings Inc (Director · Aug 26, 2015 – May 19, 2017 · Past) | Director · Since at least Jan 24, 2024 |
| Matthew Link Other companies: Sight Sciences, Inc. (Chief Commercial Officer · Since at least Sep 11, 2023) | Director · Since at least Jan 24, 2024 |
| Pete O'Heeron Other companies: Liberty Star Uranium & Metals Corp. (COB, Secretary, Treasurer, Director · Since at least Jul 31, 2019) | CHIEF EXECUTIVE OFFICER, Director · Since at least Jan 24, 2024 |
| Stacy Ann Coen Other companies: ImmunoGen Inc (SVP & CHIEF BUSINESS OFFICER · May 20, 2022 – Feb 12, 2024 · Past) | Director · Since at least Jan 24, 2024 |
| Brain Health | Director · Since at least Aug 24, 2026 |
| Hamid Khoja | Chief Scientific Officer · Since at least Jan 24, 2024 |
| Jason D. Davis | Chief Financial Officer · Since at least Jan 7, 2026 |
| Kathleen Rubins | Board of Directors · Since at least Jul 9, 2026 |
| Leigh Steinberg | Board of Directors · Since at least Aug 24, 2026 |
| Pete O’Heeron | Chairman/Founder/CEO · Since at least Oct 14, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Richard C. Cilento | Board of Directors · Since at least Nov 5, 2026 |
| Ruben Garcia | General Counsel · Since at least Mar 1, 2024 |
| Victoria Niklas | Director · Since at least Jan 24, 2024 |
Log in to ask 6ix AI your own questions about FibroBiologics, Inc.